CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.31% | -9,139.61% | -100.65% | 24.63% | 229.08% |
| Total Depreciation and Amortization | 280.60% | -61.38% | -9.87% | -6.78% | -3.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.50% | -12.18% | -18.71% | 16.59% | 25.07% |
| Change in Net Operating Assets | 113.02% | 81.57% | 61.99% | -14.79% | -44.44% |
| Cash from Operations | -49.49% | 1.30% | 25.14% | -5.70% | 3.96% |
| Capital Expenditure | -258.27% | 570.37% | 77.31% | -48.75% | -321.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,657.05% | 100.41% | -348.52% | 101.87% | -16.34% |
| Cash from Investing | -3,384.51% | 100.57% | -349.58% | 102.15% | -16.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,478.26% | -99.73% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,478.26% | -99.73% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.48% | -1,133.82% | -84.96% | 478.49% | 1.44% |